DescriptionNPM1-ALK fusion protein p80 is derived from the fusion of the N-terminal oligomerization domain of NPM1 (1–110 aa) and the C-terminal tyrosine kinase domain of ALK (1058–1620 aa). In these malignancies, the homo-dimerization of NPM1-ALK leads the constitutive activation of a ...
如果你对CBP20032RNPM1(E5)-ALK(E20) Fusion 标准品感兴趣,想了解更详细的产品信息,填写下表直接与厂家联系: 产品: 您的单位: 您的姓名: 联系电话: 常用邮箱: 省份: 详细地址: 补充说明: 验证码: 请输入计算结果(填写阿拉伯数字),如:三加四=7 ...
NPM1-ALK overexpression-driven toxicity in ALCL is partner dependent and driven by phosphorylation of novel substrates leading to overstimulation of biosyn... JH Schatz,SS Rajan,A Amin,... - 《Hematological Oncology》 被引量: 0发表: 2017年 NPM-ALK fusion kinase of anaplastic large-cell ...
Children with lymphomas driven by NPM1-ALK fusion proteins achieved an objective response rate to ALK inhibition therapy of 54-90% in clinical trials. However, a subset of patients progress within the first 3 months of treatment. The mechanism for the development of ALK inhibitor resistance is ...
Anaplastic lymphoma kinase (ALK) is an orphan receptor tyrosine kinase originally identified as part of the nucleophosmin (NPM)-ALK fusion gene in anaplastic large-cell lymphomas having a translocation [7–9]. The activated ALK kinase can act as an oncogene in different cell systems and induce ...
Abstract The mechanisms of malignant cell transformation mediated by the oncogenic anaplastic lymphoma kinase (ALK) tyrosine kinase remain only partially understood. In this study, we report that T-cell lymphoma (TCL) cells carrying the nucleophosmin (NPM)/ALK fusion protein (ALK+ TCL) strongly expr...
NPM1(E4)-ALK(E20) Fusion product informationadd product+ Item No Product Name Pre-order Operate CBP20032RNPM1(E4)-ALK(E20) Fusionremove Inquiry description Contact: Company Name: Phone: Email: Verification Code: SUBMIT
ALK fusion gene variety. 通过对API2?MALT1和NPM?ALK融合基因的mRNA设计引物,经过逆转录PCR后对产物进行测序分析,本试剂盒可以实现API2?MALT1和NPM?ALK融合基因的快速,准确,高通量的检测. By API2? MALT1 and NPM? ALK fusion gene mRNA primers were designed, after the RT-PCR products were sequenced,...
The kit can be used for detecting API2-MALT1 (A1446-M814), API2-MALT1 (A1446-M1123), API2-MALT1 (A1446-M1150) and NPM-ALK fusion genes in one time. Primers are designed for mRNAs (messenger ribonucleic acids) of the API2-MALT1 and NPM-ALK fusion genes and a product is ...
In summary, our preclinical results suggest gilteritinib has therapeutic potential for the treatment of ALCL cells expressing NPM1-ALK and other ALK /ALK-fusion driven hematologic or solid malignancies.Lin: Jazz Pharmaceuticals: Honoraria; Pfizer: Membership on an entity's Board of Directors or ...